Matches in Wikidata for { <http://www.wikidata.org/entity/Q91616165> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q91616165 description "article scientifique publié en 2020" @default.
- Q91616165 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q91616165 description "scientific article published on 06 April 2020" @default.
- Q91616165 description "wetenschappelijk artikel" @default.
- Q91616165 description "наукова стаття, опублікована 6 квітня 2020" @default.
- Q91616165 name "Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5 ): The phase 2, multicenter N-Road study" @default.
- Q91616165 name "Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5 ): The phase 2, multicenter N-Road study" @default.
- Q91616165 type Item @default.
- Q91616165 label "Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5 ): The phase 2, multicenter N-Road study" @default.
- Q91616165 label "Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5 ): The phase 2, multicenter N-Road study" @default.
- Q91616165 prefLabel "Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5 ): The phase 2, multicenter N-Road study" @default.
- Q91616165 prefLabel "Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5 ): The phase 2, multicenter N-Road study" @default.
- Q91616165 P1433 Q91616165-684CBFCB-BCCC-437C-B860-635E36DCD5EC @default.
- Q91616165 P1476 Q91616165-FA6D3068-4B50-49B2-8BFD-98C2060AB9D2 @default.
- Q91616165 P2093 Q91616165-00F58731-586A-453D-B7A5-A22BFC50A5AB @default.
- Q91616165 P2093 Q91616165-0BAF49A1-66D7-4EEE-A85A-A1726D28C0C6 @default.
- Q91616165 P2093 Q91616165-5D8522EF-E3DC-45C8-8247-EDAEB8405A68 @default.
- Q91616165 P2093 Q91616165-7317D07F-070B-475D-B81B-CA0A3363A546 @default.
- Q91616165 P2093 Q91616165-9D0FE389-D3BA-46B5-9A87-C09E6CCBF93A @default.
- Q91616165 P2093 Q91616165-C81A5284-DF02-4F58-97E5-849DA2268CE9 @default.
- Q91616165 P2093 Q91616165-CA546B31-34E0-46BF-A0BA-438A37F3923F @default.
- Q91616165 P2093 Q91616165-E0968B36-2A75-46AE-B3FC-66DC69AF18E3 @default.
- Q91616165 P2093 Q91616165-E44362CD-81D4-4B05-A81A-32FF0AAD5C41 @default.
- Q91616165 P2093 Q91616165-EEE05804-A35E-478E-9458-CDA65876B833 @default.
- Q91616165 P2093 Q91616165-EF91E1EA-A79D-4FBE-B30F-5C7443C72BA7 @default.
- Q91616165 P2093 Q91616165-F57F47D4-FE43-4D8F-8213-114A0F37CC74 @default.
- Q91616165 P31 Q91616165-255944EB-4CDE-4019-AFB9-F65F7C21F968 @default.
- Q91616165 P356 Q91616165-9BC07E69-1342-4B4A-86D6-571EBEA05A69 @default.
- Q91616165 P50 Q91616165-310255F7-EE09-4A31-A4E5-CEB4802F7206 @default.
- Q91616165 P50 Q91616165-90BE8600-E5BE-4492-9A0C-7D0C1BFEA69F @default.
- Q91616165 P577 Q91616165-5B2F10B6-B9E7-4FAB-87E6-6501C34466D0 @default.
- Q91616165 P698 Q91616165-1CBFD663-025E-4011-8795-97C089119156 @default.
- Q91616165 P921 Q91616165-98D43FD3-7A8C-4E29-AB5D-1C79964B6B1A @default.
- Q91616165 P932 Q91616165-AE3D52C5-D419-47F3-8FA4-6044F5C9AE51 @default.
- Q91616165 P356 CAM4.3034 @default.
- Q91616165 P698 32253827 @default.
- Q91616165 P1433 Q27724564 @default.
- Q91616165 P1476 "Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5 ): The phase 2, multicenter N-Road study" @default.
- Q91616165 P2093 "Atsushi Shinagawa" @default.
- Q91616165 P2093 "Hisashi Wakita" @default.
- Q91616165 P2093 "Hisayuki Yokoyama" @default.
- Q91616165 P2093 "Junichi Hisatake" @default.
- Q91616165 P2093 "Kazuhisa Fujikawa" @default.
- Q91616165 P2093 "Kei-Ji Sugimoto" @default.
- Q91616165 P2093 "Satoru Hara" @default.
- Q91616165 P2093 "Seiichi Shimizu" @default.
- Q91616165 P2093 "Shigehisa Tamaki" @default.
- Q91616165 P2093 "Tadahiko Igarashi" @default.
- Q91616165 P2093 "Takeaki Sugawara" @default.
- Q91616165 P2093 "Toshiaki Yujiri" @default.
- Q91616165 P31 Q13442814 @default.
- Q91616165 P356 "10.1002/CAM4.3034" @default.
- Q91616165 P50 Q87822646 @default.
- Q91616165 P50 Q91616158 @default.
- Q91616165 P577 "2020-04-06T00:00:00Z" @default.
- Q91616165 P698 "32253827" @default.
- Q91616165 P921 Q729735 @default.
- Q91616165 P932 "7286457" @default.